Cargando…
Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Impact Journals LLC
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6557200/ https://www.ncbi.nlm.nih.gov/pubmed/31217910 http://dx.doi.org/10.18632/oncotarget.27011 |
| _version_ | 1783425435610120192 |
|---|---|
| author | Byrd, John C. Smith, Stephen Wagner-Johnston, Nina Sharman, Jeff Chen, Andy I. Advani, Ranjana Augustson, Bradley Marlton, Paula Commerford, S. Renee Okrah, Kwame Liu, Lichuan Murray, Elaine Penuel, Elicia Ward, Ashley F. Flinn, Ian W. |
| author_facet | Byrd, John C. Smith, Stephen Wagner-Johnston, Nina Sharman, Jeff Chen, Andy I. Advani, Ranjana Augustson, Bradley Marlton, Paula Commerford, S. Renee Okrah, Kwame Liu, Lichuan Murray, Elaine Penuel, Elicia Ward, Ashley F. Flinn, Ian W. |
| author_sort | Byrd, John C. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6557200 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | Impact Journals LLC |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-65572002019-06-19 Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL Byrd, John C. Smith, Stephen Wagner-Johnston, Nina Sharman, Jeff Chen, Andy I. Advani, Ranjana Augustson, Bradley Marlton, Paula Commerford, S. Renee Okrah, Kwame Liu, Lichuan Murray, Elaine Penuel, Elicia Ward, Ashley F. Flinn, Ian W. Oncotarget Correction Impact Journals LLC 2019-06-04 /pmc/articles/PMC6557200/ /pubmed/31217910 http://dx.doi.org/10.18632/oncotarget.27011 Text en Copyright: © 2019 Byrd et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
| spellingShingle | Correction Byrd, John C. Smith, Stephen Wagner-Johnston, Nina Sharman, Jeff Chen, Andy I. Advani, Ranjana Augustson, Bradley Marlton, Paula Commerford, S. Renee Okrah, Kwame Liu, Lichuan Murray, Elaine Penuel, Elicia Ward, Ashley F. Flinn, Ian W. Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL |
| title | Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL |
| title_full | Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL |
| title_fullStr | Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL |
| title_full_unstemmed | Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL |
| title_short | Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL |
| title_sort | correction: first-in-human phase 1 study of the btk inhibitor gdc-0853 in relapsed or refractory b-cell nhl and cll |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6557200/ https://www.ncbi.nlm.nih.gov/pubmed/31217910 http://dx.doi.org/10.18632/oncotarget.27011 |
| work_keys_str_mv | AT byrdjohnc correctionfirstinhumanphase1studyofthebtkinhibitorgdc0853inrelapsedorrefractorybcellnhlandcll AT smithstephen correctionfirstinhumanphase1studyofthebtkinhibitorgdc0853inrelapsedorrefractorybcellnhlandcll AT wagnerjohnstonnina correctionfirstinhumanphase1studyofthebtkinhibitorgdc0853inrelapsedorrefractorybcellnhlandcll AT sharmanjeff correctionfirstinhumanphase1studyofthebtkinhibitorgdc0853inrelapsedorrefractorybcellnhlandcll AT chenandyi correctionfirstinhumanphase1studyofthebtkinhibitorgdc0853inrelapsedorrefractorybcellnhlandcll AT advaniranjana correctionfirstinhumanphase1studyofthebtkinhibitorgdc0853inrelapsedorrefractorybcellnhlandcll AT augustsonbradley correctionfirstinhumanphase1studyofthebtkinhibitorgdc0853inrelapsedorrefractorybcellnhlandcll AT marltonpaula correctionfirstinhumanphase1studyofthebtkinhibitorgdc0853inrelapsedorrefractorybcellnhlandcll AT commerfordsrenee correctionfirstinhumanphase1studyofthebtkinhibitorgdc0853inrelapsedorrefractorybcellnhlandcll AT okrahkwame correctionfirstinhumanphase1studyofthebtkinhibitorgdc0853inrelapsedorrefractorybcellnhlandcll AT liulichuan correctionfirstinhumanphase1studyofthebtkinhibitorgdc0853inrelapsedorrefractorybcellnhlandcll AT murrayelaine correctionfirstinhumanphase1studyofthebtkinhibitorgdc0853inrelapsedorrefractorybcellnhlandcll AT penuelelicia correctionfirstinhumanphase1studyofthebtkinhibitorgdc0853inrelapsedorrefractorybcellnhlandcll AT wardashleyf correctionfirstinhumanphase1studyofthebtkinhibitorgdc0853inrelapsedorrefractorybcellnhlandcll AT flinnianw correctionfirstinhumanphase1studyofthebtkinhibitorgdc0853inrelapsedorrefractorybcellnhlandcll |